{"organizations": [], "uuid": "3953f219d9821633260a4fd3e2ed2d9374272b16", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-medicenna-amends-protocol-of-phase/brief-medicenna-amends-protocol-of-phase-2b-recurrent-glioblastoma-study-of-mdna55-idUSFWN1S90NF", "country": "US", "domain_rank": 408, "title": "BRIEF-Medicenna Amends Protocol Of Phase 2B Recurrent Glioblastoma Study Of MDNA55", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-02T14:07:00.000+03:00", "replies_count": 0, "uuid": "3953f219d9821633260a4fd3e2ed2d9374272b16"}, "author": "", "url": "https://www.reuters.com/article/brief-medicenna-amends-protocol-of-phase/brief-medicenna-amends-protocol-of-phase-2b-recurrent-glioblastoma-study-of-mdna55-idUSFWN1S90NF", "ord_in_thread": 0, "title": "BRIEF-Medicenna Amends Protocol Of Phase 2B Recurrent Glioblastoma Study Of MDNA55", "locations": [], "entities": {"persons": [{"name": "recurren", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "medicenna therapeutics corp", "sentiment": "none"}, {"name": "glioblastoma", "sentiment": "none"}, {"name": "glioblastoma study of mdna55 reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "medicenna therapeutics corp", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 2, 2018 / 11:08 AM / Updated 10 minutes ago BRIEF-Medicenna Amends Protocol Of Phase 2B Recurrent Glioblastoma Study Of MDNA55 Reuters Staff 1 Min Read\nMay 2 (Reuters) - Medicenna Therapeutics Corp:\n* MEDICENNA AMENDS PROTOCOL OF PHASE 2B RECURRENT GLIOBLASTOMA STUDY OF MDNA55 IN RESPONSE TO STRONG SAFETY DATA AND EARLY EFFICACY READ-OUTS\n* MEDICENNA THERAPEUTICS - AMENDS PROTOCOL OF PHASE 2B RECURRENT GLIOBLASTOMA STUDY WILL EXTEND EXPECTED TIMING TO COMPLETE ENROLLMENT IN STUDY TO Q42018\n* MEDICENNA THERAPEUTICS CORP - HALF PATIENTS IN ONGOING PHASE 2B STUDY OF MDNA55 IN RECURRENT GLIOBLASTOMA (RGBM) HAVE BEEN RECRUITED Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-02T14:07:00.000+03:00", "crawled": "2018-05-02T14:25:57.011+03:00", "highlightTitle": ""}